Summit Therapeutics Inc. — Director's Dealing 2025

Jan 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2025-01-02

Reporting Person: Zanganeh Mahkam (Director, Co-Chief Executive Officer, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-02	Stock Option (right to buy)	$18.35	A	10724	Acquired	2035-01-02	Common Stock (10724)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	31000	Direct
Common Stock	10199776	Indirect
Common Stock	25457666	Indirect
Common Stock	50000	Indirect
Common Stock	551695096	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrant (right to buy)	$1.58	2029-12-24	Common Stock (3985055)	3985055	Indirect
Stock Option (right to buy)	$2.64	2034-01-02	Common Stock (74545)	74545	Indirect

Footnotes

F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

F2: The Reporting Person acquired beneficial ownership of these securities upon her marriage to the beneficial owner of the securities on December 18, 2024.

F3: The option was granted on January 2, 2025 to the Reporting Person's spouse. The shares underlying the option shall vest in four quarterly installments, subject to continued service on each vesting date.

F4: The option was granted on January 2, 2024 to the Reporting Person's spouse. The shares underlying the option are fully vested.